Mindray(300760)2024-10-29 13:21Financial Performance - Revenue for the third quarter was 8,954,208,694 RMB, a 1.43% increase year-over-year[2] - Net profit attributable to shareholders for the third quarter was 3,076,337,561 RMB, a 9.31% decrease year-over-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was 29,484,805,493 RMB, a 7.99% increase year-over-year[2] - Cumulative net profit attributable to shareholders from the beginning of the year to the end of the reporting period was 10,637,075,305 RMB, an 8.16% increase year-over-year[2] - Revenue for the first three quarters of 2024 reached 294.85 billion yuan, a year-on-year increase of 7.99%[12] - Net profit attributable to shareholders was 106.37 billion yuan, a year-on-year increase of 8.16%[12] - Total revenue for the current period reached 29.48 billion yuan, an increase from 27.30 billion yuan in the previous period[20] - Net profit attributable to the parent company increased to 28.58 billion yuan from 24.68 billion yuan in the previous period[19] - Net profit attributable to parent company shareholders reached RMB 10.637 billion, an increase from RMB 9.834 billion in the previous period[21] - Basic earnings per share increased to RMB 8.7808, up from RMB 8.1216 in the previous period[21] - Comprehensive income attributable to parent company shareholders was RMB 10.564 billion, compared to RMB 10.033 billion in the previous period[21] Cash Flow and Financial Position - Operating cash flow for the period increased by 42.50% year-over-year, reaching 11,072,880,996 RMB[2][6] - Total assets at the end of the reporting period were 57,601,486,436 RMB, a 20.15% increase compared to the end of the previous year[2] - Shareholders' equity attributable to the company at the end of the reporting period was 37,093,899,069 RMB, a 12.12% increase compared to the end of the previous year[2] - Total assets increased to 57.60 billion yuan from 47.94 billion yuan in the previous period[19] - Total liabilities increased to 15.59 billion yuan from 14.59 billion yuan in the previous period[18] - Total equity increased to 42.01 billion yuan from 33.35 billion yuan in the previous period[19] - Operating cash flow increased to RMB 11.073 billion, up from RMB 7.771 billion in the previous period[22] - Cash and cash equivalents at the end of the period decreased to RMB 15.583 billion from RMB 18.668 billion at the beginning of the period[23] - Tax refunds received increased to RMB 866.82 million, up from RMB 769.52 million in the previous period[22] - Payments for employee benefits and wages increased to RMB 6.429 billion, compared to RMB 5.649 billion in the previous period[22] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 72,917[8] - Smartco Development Limited holds 26.98% of the shares, totaling 327,072,335 shares[8] - Magnifice (HK) Limited holds 24.49% of the shares, totaling 296,951,000 shares, with 36,820,000 shares pledged[8] - Hong Kong Securities Clearing Company Limited holds 12.01% of the shares, totaling 145,616,297 shares[8] - Ever Union (H.K.) Limited holds 4.25% of the shares, totaling 51,482,379 shares[8] - The China Industrial and Commercial Bank Limited - E Fund ChiNext ETF holds 1.20% of the shares, totaling 14,541,569 shares[8] - The China Industrial and Commercial Bank Limited - Huatai-PineBridge CSI 300 ETF holds 0.95% of the shares, totaling 11,520,049 shares[8] - Shenzhen Ruifu Management Consulting Partnership holds 0.86% of the shares, totaling 10,405,351 shares[8] - The China Industrial and Commercial Bank Limited - China Europe Healthcare Hybrid Fund holds 0.84% of the shares, totaling 10,183,344 shares[8] - Shenzhen Ruilong Consulting Services Partnership holds 0.84% of the shares, totaling 10,156,738 shares[8] Market and Product Performance - International market revenue grew by over 18%, with Europe and Asia-Pacific markets growing by more than 30%[12] - Domestic market revenue grew by less than 2% due to delayed hospital procurement and tight construction funds[12] - In vitro diagnostics product line grew by over 20%, with international in vitro diagnostics growing by over 30%[12] - Medical imaging product line grew by over 10%, driven by the Resona A20 ultrasound system[12] - Life information and support product line declined by over 10%, with domestic sales dropping by more than 20%[12] Research and Development - R&D investment in the first three quarters of 2024 was 28.43 billion yuan, accounting for 9.64% of revenue[13] - The company launched 10 new chemical luminescence immunoassay reagents and 10 biochemical analysis reagents in Q3 2024[13] - Cumulative patent applications reached 11,358, with 8,115 invention patents and 5,563 authorized patents[13] - R&D expenses increased to 2.59 billion yuan from 2.51 billion yuan in the previous period[20] Operational Costs and Liabilities - Operating costs for the current period were 17.87 billion yuan, up from 16.55 billion yuan in the previous period[20] - Inventory increased to 4.86 billion yuan from 3.98 billion yuan in the previous period[17] - Accounts receivable increased to 3.60 billion yuan from 3.30 billion yuan in the previous period[17] - Short-term borrowings decreased to 5.68 million yuan from 7.75 million yuan in the previous period[18] - Investment cash outflow was RMB 7.962 billion, a significant increase from RMB 5.910 billion in the previous period[22] - Financing cash outflow was RMB 6.969 billion, compared to RMB 5.593 billion in the previous period[23] Earnings and Shareholder Returns - Basic earnings per share for the third quarter were 2.5364 RMB, a 9.50% decrease year-over-year[2] - Weighted average return on equity for the third quarter was 7.93%, a decrease of 1.72 percentage points year-over-year[2] - Non-recurring gains and losses for the third quarter amounted to 19,324,724 RMB[4] - Sales revenue from goods and services reached RMB 31.578 billion, compared to RMB 26.496 billion in the previous period[22]